CA2373016A1 - Method for diminishing specific immune reactions - Google Patents

Method for diminishing specific immune reactions

Info

Publication number
CA2373016A1
CA2373016A1 CA 2373016 CA2373016A CA2373016A1 CA 2373016 A1 CA2373016 A1 CA 2373016A1 CA 2373016 CA2373016 CA 2373016 CA 2373016 A CA2373016 A CA 2373016A CA 2373016 A1 CA2373016 A1 CA 2373016A1
Authority
CA
Grant status
Application
Patent type
Prior art keywords
antigen
presenting cell
monoantigenic
receptors
according
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA 2373016
Other languages
French (fr)
Inventor
Ahmed Sheriff
Frank Gebauer
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
GENETHOR GmbH
Original Assignee
Genethor Gmbh
Ahmed Sheriff
Frank Gebauer
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06Animal cells or tissues; Human cells or tissues ; Not used, see subgroups
    • C12N5/0602Vertebrate cells
    • C12N5/0634Cells from the blood or the immune system
    • C12N5/0645Macrophages, e.g. Kuepfer cells in the liver; Monocytes
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K35/00Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K2035/122Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells for inducing tolerance or supression of immune responses
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/51Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/515Animal cells
    • A61K2039/5154Antigen presenting cells [APCs], e.g. dendritic cells, macrophages
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2510/00Genetically modified cells

Abstract

The invention relates to an antigen-presenting cell which mainly presents predetermined antigens (monoantigenic antigen-presenting cell) and which is characterized in that the monoantigenic antigen-presenting cell is capable of dividing and one of the functions of co-stimulator receptors such as a B7 and/or CD40 receptor is suppressed.

Claims (24)

1. An antigen-presenting cell which predominantly presents predefined anti-gens, characterized in that - said antigen-presenting cell exhibits an enhanced expression of said predefined antigens due to transformation of an antigen-presenting cell with nucleic-acid containing material; and - said antigen-presenting cell substantially presents only said prede-fined antigens and one of the functions of co-stimulatory receptors of the cell, such as a B7 and/or CD40 receptor, is suppressed.
2. The monoantigenic antigen-presenting cell according to claim 1, character-ized in that said monoantigenic antigen-presenting cell is a monocyte, a dendritic cell and/or a macrophage.
3. The monoantigenic antigen-presenting cell according to claim 1 and/or 2, characterized in that said monoantigenic antigen-presenting cell has an in-creased number of homing receptors, such as CD44.
4. The monoantigenic antigen-presenting cell according to at least one of claims 1 to 3, characterized in that a transformation causes a suppression of functions of the B7, CD40 receptors and/or an increase of the number of homing receptors.
5. The monoantigenic antigen-presenting cell according to at least one of claims 1 to 4, containing antisense nucleic acids for preventing the expres-sion of B7 and/or CD40 receptors.
6. The monoantigenic antigen-presenting cell according to at least one of claims 1 to 4, containing nucleic acids which cause a suppression of the ex-pression of B7 and/or CD40 receptors by co-suppression.
7. The monoantigenic antigen-presenting cell according to at least one of claims 1 to 6, containing nucleic acids which cause expression of proteins or peptides having structures with affinity for B7 and/or CD40 receptors.
8. The monoantigenic antigen-presenting cell according to claim 7, wherein said proteins having structures with affinity for B7 receptors are CTLA4, CD28, antibodies, F(ab)2, scFv and/or F ab fragments.
9. The monoantigenic antigen-presenting cell according to claim 7 and/or 8, wherein said nucleic acids code for a signal sequence, or the expression products have a signal sequence which causes the expression products to remain in the endoplasmic reticulum, the Golgi apparatus, the trans-Golgi network, or intracellular vesicles.
10. The monoantigenic antigen-presenting cell according to at least one of claims 1 to 9, characterized in that said monoantigenic antigen-presenting cell is transformed for the expression of antigens with nucleic acids which enable the transport of the expressed antigens into MHC II compartments of the cells.
11. The monoantigenic antigen-presenting cell according to at least one of claims 1 to 10, characterized in that said nucleic acids are DNA, RNA, oligo-nucleotides, polynucleotides, ribozymes, peptide nucleic acids (PNA).
12. The monoantigenic antigen-presenting cell according to claim 11, charac-terized in that said DNA has regulatory elements, such as enhancers, pro-moters, polyA-coding 3' termini for the transcription of the DNA into RNA
which contains RNA regulatory elements for the translation of the RNA into protein.
13. A method for the preparation of the monoantigenic antigen-presenting cell according to at least one of claims 1 to 12 by ex vivo or in vivo methods.
14. The method according to claim 13, wherein an antigen-presenting cell is transformed ex vivo or in vivo into a monoantigenic antigen-presenting cell by treatment with viruses, viral vectors, bacterial vectors, plasmids, which are introduced into the monoantigenic antigen-presenting cell by viral gene transfer, electroporation techniques, iontophoresis, ballistic methods and/or other techniques for the introduction of molecules.
15. The method according to claim 13 and/or 14, wherein an antigen-presenting cell or a monoantigenic antigen-presenting cell is transformed into a cell with a suppressed function of co-stimulatory receptors by treatment with viruses, viral vectors, bacterial vectors, plasmids, which are introduced by viral gene transfer, electroporation techniques, iontophoresis, ballistic meth-ods and/or other techniques for the introduction of molecules, the expres-sion of co-stimulatory receptors is prevented, or the co-stimulatory recep-tors are prevented from stimulating T cells bound to the monoantigenic an-tigen-presenting cell by reaction with affinity structures.
16. The method according to at least one of claims 13 to 15, wherein molecules such as antibodies, proteins, peptides, peptidomimetics, CTLA4, CD28, CD40L and/or components and/or combinations of these molecules which bind, for example, B7-1, B7-2, CD40, which hinders co-stimulation of the T
cell occurring in the presence of antigen-presentation, are contacted with the monoantigenic antigen-presenting cell or antigen-presenting cell.
17. The method according to at least one of claims 13 to 16, wherein the molecules as defined in claim 16 are transferred into the monoantigenic an-tigen-presenting cell or antigen-presenting cell by vehicles, such as lipo-somes, hydrogels, cyclodextrins, biodegradable nanocapsules, bioadhesive microspheres and/or by electroporation techniques, iontophoresis, ballistic methods and/or other techniques for the introduction of molecules.
18. The method according to at least one of claims 13 to 17, wherein nucleic acids are transferred by viruses, viral vectors, bacterial vectors, plasmids, which are introduced into the monoantigenic antigen-presenting cell or anti-gen-presenting cell by viral gene transfer, electroporation techniques, ionto-phoresis, ballistic methods and/or other techniques for the introduction of molecules.
19. A medicament containing at least one monoantigenic antigen-presenting cell according to at least one of claims 1 to 12.
20. A medicament according to claim 19, wherein at least one monoantigenic antigen-presenting cell is formulated as an infusion for intravenous or intra-peritoneal administration.
21. Use of at least one monoantigenic antigen-presenting cell according to at least one of claims 1 to 12 for the preparation of a medicament for the treatment of undesirable immune reactions, such as auto-immune diseases and allergies, or deliberately induced immune reactions, as in immuniza-tions.
22. Use of at least one monoantigenic antigen-presenting cell according to at least one of claims 1 to 12 for the preparation of a medicament for the treatment of immune reactions against allologous and/or xenologous tissue parameters.
23. The use according to claim 21, wherein the immune reactions to be treated are related to antigens or their gene sequences and/or parts thereof se-lected from the group consisting of - enzymes, their gene sequences and/or partial sequences, especially glutamic acid decarboxylase (GAD), receptor-type protein tyrosine-phosphatase IA-2beta, H+K+ATPase, U1RNP, transglutaminase, ar-gininosuccinate-lyase (ASL), tyrosinase-related protein-2, thyroid peroxidase, factor VIII, factor IX;
- receptors, their gene sequences and/or partial sequences, especially acetylcholine receptor of the nicotine type, myasthenia gravis, .beta.1-adrenergic receptor, .alpha.1-adrenergic receptor, angiotensin-2-AT1 re-ceptor, glutamate receptor, thyrotropin-stimulating hormone (TSH) receptor, LFA-1, HLA-B27, epididymal protein DE, zona pellucida (ZP)-3 glycoprotein, zona pellucida (ZP)-4 glycoprotein, follicle-stimulating hormone (FSH) receptor, sperm immunogen SP-10 or sperm protein SP-10;
- hormones or messengers, their gene sequences and/or partial sequences, especially insulin, thyroglobulin, follicle-stimulating hor-mone (FSH), prostaglandin F2 alpha, gonadotropin-releasing hor-mone (GnRH), estradiol-17-beta, estrogen, luteinizing hormone (LH) receptor, inhibin, testosterone, androgen, chorionic gonado-tropin (CG), interleukins, interferons, cytokines, chemokines, bone morphogenetic factors, .beta.-interferon, estradiol;
- structural proteins, their gene sequences and/or partial sequences, especially myelin basic protein (MBP), proteolipid protein (PLP), myelin oligodendrocyte glycoprotein (MOG), .alpha.-fodrin, non-erythroid .alpha.-spectrin, beta-amyloid precursor protein (beta-APP), type 2 colla-gen, sperm plasma membrane protein PH-20;
- antigens, their gene sequences and/or partial sequences, especially CENP-A auto-antigen, beta2GP-I, ribosomal P protein, Ro/SSA, La/SSB, Sm/RNP, Sm, Scl-70, Jo-1, BCOADC-E2, albumin, gluca-gon, islet cell antigens, retinal S Ag;
- allergens triggering an IgE response, their gene sequences and/or partial sequences, especially Der f 1, Der f 2, Der f 3, Der p 1, Der p 2, Der p 3, Der p 4, Der p 5, Der p 8, Eur m 1, Lep d 2, Fel d 1, Can f 1, Can f 2, Mus m 1, Rat n 1, Bla g 1, Bla g 2, Bla g 4, Bla g 5, Per a 1, bee venom phospholipase A2 (PLA2), group V major allergen Phl p 5b from Timothy grass pollen, Hom s 1.
24. The use according to claim 22, wherein the immune reactions to be treated are related to allologous and/or xenologous tissue parameters, their gene sequences and/or partial sequences, especially MHC I, MHC II, rhesus fac-tor.
CA 2373016 1999-05-04 2000-05-04 Method for diminishing specific immune reactions Abandoned CA2373016A1 (en)

Priority Applications (7)

Application Number Priority Date Filing Date Title
DE19920412.8 1999-05-04
DE19920412 1999-05-04
DE19944858.2 1999-09-18
EP19990118518 EP1085085A1 (en) 1999-09-18 1999-09-18 Process for reducing specific immune reactions
EP99118518.2 1999-09-18
DE1999144858 DE19944858A1 (en) 1999-09-18 1999-09-18 A monoantigen-presenting cell capable of dividing and with suppressed functionality of the co-stimulatory receptors B7 and CD40
PCT/EP2000/003984 WO2000066715A1 (en) 1999-05-04 2000-05-04 Method for diminishing specific immune reactions

Publications (1)

Publication Number Publication Date
CA2373016A1 true true CA2373016A1 (en) 2000-11-09

Family

ID=27219128

Family Applications (1)

Application Number Title Priority Date Filing Date
CA 2373016 Abandoned CA2373016A1 (en) 1999-05-04 2000-05-04 Method for diminishing specific immune reactions

Country Status (5)

Country Link
EP (1) EP1173550B1 (en)
JP (1) JP2002542819A (en)
CA (1) CA2373016A1 (en)
DE (1) DE50013230D1 (en)
WO (1) WO2000066715A1 (en)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6858210B1 (en) 1998-06-09 2005-02-22 La Jolla Pharmaceutical Co. Therapeutic and diagnostic domain 1 β2GPI polypeptides and methods of using same
DE10038722C2 (en) * 2000-08-09 2002-07-25 Genethor Gmbh A method of reducing specific immune responses
WO2002077208A1 (en) * 2001-03-27 2002-10-03 Genethor Gmbh Antigen-dependent reduction of specific immune reactions by influencing the co-stimulation
WO2002092795A3 (en) * 2001-05-16 2003-01-09 Genethor Gmbh Intracellular bonding of costimulatory molecules
WO2003006636A1 (en) * 2001-07-12 2003-01-23 Genethor Gmbh Reduction of the stimulatory capacity of antigen-presenting cells
CN103432079A (en) 2004-05-12 2013-12-11 巴克斯特国际公司 Oligonucleotide-containing microspheres, their use for the manufacture of a medicament for treating diabetes type 1
EP2072040B1 (en) 2004-05-12 2013-05-01 Baxter International Inc. Therapeutic use of nucleic acid micropheres
EP2647712A3 (en) 2006-08-04 2013-11-20 Baxter International Inc Microsphere-based composition for preventing and/or reversing new-onset autoimmune diabetes
CN101686939B (en) 2007-04-17 2013-03-27 巴克斯特国际公司 Nucleic acid microparticles for pulmonary delivery
EP2000531A1 (en) * 2007-06-06 2008-12-10 Biomay AG Antigen presenting cells

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6077833A (en) * 1996-12-31 2000-06-20 Isis Pharmaceuticals, Inc. Oligonucleotide compositions and methods for the modulation of the expression of B7 protein
WO1999025812A1 (en) * 1997-11-14 1999-05-27 Hemosol Inc. Method for the production and use of dendritic cells
CA2321173A1 (en) * 1998-03-30 1999-10-07 I.D.M. Immuno-Designed Molecules Suppressive monocyte derived cells, process for their preparation and their uses in pharmaceutical compositions

Also Published As

Publication number Publication date Type
JP2002542819A (en) 2002-12-17 application
WO2000066715A1 (en) 2000-11-09 application
EP1173550A1 (en) 2002-01-23 application
EP1173550B1 (en) 2006-07-26 grant
DE50013230D1 (en) 2006-09-07 grant

Similar Documents

Publication Publication Date Title
DE20120493U1 (en) Device for in vitro generation of abrasion particles on implant surfaces
GB2395876B (en) Computer signal transmission system
GB2305964B (en) Safety device
WO2003029262A3 (en) The human mob-5 (il-24) receptors and uses thereof
Li et al. Evidence of plumb line variations in Europe from latitude observations.
Zimbelman et al. Medusae Fossae Formation, Mars: An assessment of possible origins utilizing early results from Mars Global Surveyor
GB2329068B (en) Lead-frame based vertical interconnect package
Kallemeyn Carbonaceous chondritic materials in the solar system
GB2343904B (en) Cage slip system and release methods
Fukuda et al. System Supporting Automatic Generation of Finite Element Using Image Information
Pendleton et al. Infrared studies of dust grains in infrared reflection nebulae.
JPH11191562K1 (en) Manufacture for producing semiconductor device
渡辺悌二 The Mount Cook Rock Avalanche of 14 December 1991
Hájek et al. New light elements of WZ Leo.
Bingham University of Sheffield
JPS63169149A (en) Dynamic transmission schedule system
GB0006317D0 (en) Method of making photovoltaic device
GB0111736D0 (en) Seat for an infant
GB9826052D0 (en) Deceleration facilitation
GB0403888D0 (en) Protective packaging system
EP1039933B8 (en) METHODS AND COMPOSITIONS FOR ENHANCING IMMUNE RESPONSE AND FOR THE PRODUCTION OF $i(IN VITRO) MABS
CA75550S (en) Corkscrew
GB9904583D0 (en) Safety modification to crash helmet
GB9813040D0 (en) Digital certification photograph system
GB9724338D0 (en) Ignition system

Legal Events

Date Code Title Description
EEER Examination request
FZDE Dead